| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | - | - | - | - | - | - | - | - | 45.762 | 104.482 |
| Total Income - EUR | - | - | - | - | - | - | - | - | 48.997 | 104.494 |
| Total Expenses - EUR | - | - | - | - | - | - | - | - | 48.348 | 93.190 |
| Gross Profit/Loss - EUR | - | - | - | - | - | - | - | - | 649 | 11.305 |
| Net Profit/Loss - EUR | - | - | - | - | - | - | - | - | 169 | 9.767 |
| Employees | - | - | - | - | - | - | - | - | 1 | 1 |
Check the financial reports for the company - Datinpharm S.r.l.
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | - | - | - | - | - | - | - | - | 1.830 | 1.161 |
| Current Assets | - | - | - | - | - | - | - | - | 46.471 | 44.584 |
| Inventories | - | - | - | - | - | - | - | - | 22.806 | 19.417 |
| Receivables | - | - | - | - | - | - | - | - | 13.982 | 13.716 |
| Cash | - | - | - | - | - | - | - | - | 9.683 | 11.451 |
| Shareholders Funds | - | - | - | - | - | - | - | - | 209 | 9.976 |
| Social Capital | - | - | - | - | - | - | - | - | 40 | 40 |
| Debts | - | - | - | - | - | - | - | - | 48.091 | 35.769 |
| Income in Advance | - | - | - | - | - | - | - | - | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "4773 - 4773" | |||||||||
| CAEN Financial Year |
4773
|
|||||||||
Comments - Datinpharm S.r.l.